X0306 4 2017-04-19 0 0001674416 CRISPR Therapeutics AG CRSP 0001682017 Novak Rodger C/O CRISPR THERAPEUTICS AG BAARERSTRASSE 14 ZUG V8 CH-6300 SWITZERLAND 1 1 0 0 Chief Executive Officer Common Shares 2017-04-19 4 M 0 47706 1.81 A 1262711 D Common Shares 2017-04-19 4 S 0 32338 17.5669 D 1230373 D Common Shares 2017-04-19 4 S 0 15368 18.6093 D 1215005 D Common Shares 2017-04-20 4 M 0 2294 1.81 A 1217299 D Common Shares 2017-04-20 4 S 0 2294 17.3722 D 1215005 D Stock Options (Right to Buy) 1.81 2017-04-19 4 M 0 47706 0.00 D 2025-09-10 Common Shares 47706 220387 D Stock Options (Right to Buy) 1.81 2017-04-20 4 M 0 2294 0.00 D 2025-09-10 Common Shares 2294 218093 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $18.045, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.06 to $19.05, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $17.53, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. /s/ Michael Esposito, attorney-in-fact 2017-04-21